Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Annual Price Revision Could Plunge Pharma Industry into Doldrums: Pfizer Japan Chief
December 5, 2016
- FDA Accepts sNDA for Abilify Maintena’s Bipolar I Disorder Indication
December 2, 2016
- Novartis Seeks Aplastic Anemia Indication for Revolade, Neoral
December 2, 2016
- Takeda to Build Dengue Vaccine Plant in Germany
December 2, 2016
- JACE for Giant Congenital Melanocytic Nevus Covered by Health Insurance: J-TEC
December 2, 2016
- Pfizer Japan Completes Transfer of Generics from Hospira Japan
December 2, 2016
- Oncolys Licenses Oncolytic Virus Telomelysin to Hengrui in China
December 2, 2016
- Shionogi Files Abuse-Deterrent Painkiller Oxycodone in Japan
December 1, 2016
- Chugai Seeks Large Vessel Vasculitis Indication for Actemra
December 1, 2016
- Signs of Growth in Prescribing SGLT-2 Inhibitors with Favorable Environment Change
November 30, 2016
- Shionogi Says UK Court Finds Its HIV Drug Patent Invalid, Set to Challenge Ruling
November 29, 2016
- Santen Eyes US Filing for Opsiria Early Next Year
November 29, 2016
- Chugai Licenses Class I PI3K Inhibitor to German Drug Maker
November 29, 2016
- Ono to Offer New Invoice Prices for Opdivo Early on to Avoid Distribution Confusion
November 29, 2016
- Prosecutors Seek 2.5 Years in Jail for Ex-Novartis Employee: Diovan Case
November 28, 2016
- Drug Makers Concerned about Cost-Effective Assessments Used for NHI Price Cuts: Survey
November 28, 2016
- Shionogi Set to Go Global with Botulinum Toxin, Gets Rights from Tokushima Univ.
November 25, 2016
- CSL Behring to Enter Japanese Hemophilia Market with Idelvion
November 25, 2016
- MSD to Distribute Bayer’s Adempas from Next Year
November 25, 2016
- Ninlaro Earns Conditional Approval in Europe: Takeda
November 25, 2016
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…